Glucosamine Sulfate

In 137 participants with knee osteoarthritis who had taken glucosamine for six months, stopping it and switching to placebo did not worsen symptoms compared to continued use.

In 51 participants with rheumatoid arthritis, 1500mg daily glucosamine significantly improved symptoms compared to placebo, though it did not affect inflammation markers.

In 50 participants with knee pain mostly from osteochondritis, 2000mg daily glucosamine showed equivocal but potentially positive symptom improvement.

In 212 participants with knee osteoarthritis, glucosamine sulfate reduced symptoms, improved pain and mobility, and X-rays showed prevention of progressive joint damage compared to placebo.

In 50 participants with knee pain mostly from osteochondritis, 2000mg daily glucosamine showed equivocal but potentially positive symptom improvement.

In 51 participants with rheumatoid arthritis, 1500mg daily glucosamine significantly improved symptoms compared to placebo, though it did not affect inflammation markers.

In 212 participants with knee osteoarthritis, glucosamine sulfate reduced symptoms, improved pain and mobility, and X-rays showed prevention of progressive joint damage compared to placebo.

In over 260,000 participants, glucosamine users had an 8% lower risk of developing diabetes compared to non-users, attributed to anti-inflammatory effects.

In over 400,000 adults, regular glucosamine use was associated with 17% lower risk of developing type 2 diabetes over eight years.

In over 260,000 participants, glucosamine users had an 8% lower risk of developing diabetes compared to non-users, attributed to anti-inflammatory effects.

In over 400,000 adults, regular glucosamine use was associated with 17% lower risk of developing type 2 diabetes over eight years.